CVS Pays $315M to Settle DOJ Opioid Dispensing Allegations

CVS Health will pay $315 million to resolve federal allegations that its pharmacies unlawfully dispensed opioids and other controlled substances for more than a decade, billing Medicare and other government programs for prescriptions lacking legitimate medical purposes.

The Justice Department settlement covers dispensing practices from October 2013 through December 2025. Federal prosecutors accused the Woonsocket, Rhode Island-based chain of filling orders involving excessive opioid quantities, premature refills and dangerous drug combinations known as “trinity” prescriptions — a mix of an opioid, a benzodiazepine and a muscle relaxant that carries a severe risk of fatal respiratory depression. The Drug Enforcement Administration has long flagged trinity combinations as a primary indicator of diversion schemes.

Prosecutors alleged CVS pharmacists routinely ignored red flags signaling illegitimate prescriptions and accepted orders from suspected pill mills. Beyond individual pharmacy failures, the Justice Department pointed to corporate performance metrics, incentive compensation structures and staffing policies that prioritized prescription volume over patient safety.

CVS denied the allegations and admitted no wrongdoing. The company defended its workforce of more than 27,000 pharmacists, calling them highly trained professionals who help keep Americans healthy.

Associate Attorney General Stanley E. Woodward Jr. characterized the agreement as a milestone in holding bad actors accountable within the broader federal effort to combat the opioid epidemic.

The resolution arrives during a turbulent period for the largest pharmacy chain in the United States. Facing mounting pressure from investors and industry analysts — including public calls for a breakup discussed by Barron’s Roundtable panelists — CVS initiated a strategic review of its sprawling business model. The company operates retail pharmacies, the Caremark pharmacy benefits manager and the Aetna health insurance division. Retail pharmacy margins have compressed significantly due to lower reimbursement rates from pharmacy benefit managers and increased generic drug competition, intensifying scrutiny of how the conglomerate manages compliance risks across its divisions.

This $315 million agreement is distinct from the roughly $5 billion CVS agreed to pay in late 2022 to settle thousands of lawsuits brought by state attorneys general, municipalities and Native American tribal governments. That earlier litigation focused on the company’s broader role in fueling the national opioid crisis. The new settlement targets specific violations of the False Claims Act, addressing fraudulent billing to federal health care programs rather than general public nuisance claims.

Federal authorities have pursued similar enforcement actions against competing chains. Walmart recently agreed to pay $50 million to settle parallel allegations that its pharmacies filled illegal opioid prescriptions, signaling an aggressive, industry-wide crackdown by the Justice Department on retail dispensing standards.

Under a separate agreement with the DEA accompanying the financial settlement, CVS must implement new operational safeguards. The mandated reforms include establishing a dedicated hotline for employees and the public to report suspected illegal dispensing, proactively monitoring prescription patterns across its locations and creating formal procedures to evaluate prescribers flagged for potential misconduct.

CVS operates approximately 9,000 retail pharmacy locations nationwide.